

File No. 220953

Committee Item No. 3

Board Item No. 20

## COMMITTEE/BOARD OF SUPERVISORS

### AGENDA PACKET CONTENTS LIST

Committee: Budget and Finance Committee Date September 28, 2022

Board of Supervisors Meeting Date October 18, 2022

#### Cmte Board

- Motion
- Resolution
- Ordinance
- Legislative Digest
- Budget and Legislative Analyst Report
- Youth Commission Report
- Introduction Form
- Department/Agency Cover Letter and/or Report
- MOU
- Grant Information Form
- Grant Budget
- Subcontract Budget
- Contract/Agreement
- Form 126 – Ethics Commission
- Award Letter
- Application
- Public Correspondence

#### OTHER (Use back side if additional space is needed)

<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____

Completed by: Brent Jalipa Date September 22, 2022

Completed by: Brent Jalipa Date October 6, 2022

1 [Accept and Expend Grant - Retroactive - National Institutes of Health - The Regents of the  
2 University of California, San Francisco - University of California, San Francisco - Gladstone  
3 Center for Acquired Immunodeficiency Syndrome Research - \$233,512]

4 **Resolution retroactively authorizing the Department of Public Health to accept and**  
5 **expend a grant increase in the amount of \$95,155 from the National Institutes of Health**  
6 **through The Regents of the University of California, San Francisco for a total amount of**  
7 **\$233,512 for participation in a program, entitled “University of California, San Francisco**  
8 **- Gladstone Center for Acquired Immunodeficiency Syndrome Research,” for the**  
9 **period of September 1, 2017, to August 31, 2022.**

10  
11 WHEREAS, The National Institutes of Health (NIH), through The Regents of the  
12 University of California, San Francisco (UCSF) as a pass-through entity, has agreed to fund  
13 the Department of Public Health (DPH) in the amount of \$233,512 for participation in a  
14 program, entitled “University of California, San Francisco - Gladstone Center for Acquired  
15 Immunodeficiency Syndrome (AIDS) Research,” for the period of September 1, 2017, to  
16 August 31, 2022; and

17 WHEREAS, The Healthy Outcomes for People Everywhere (HOPE) project will  
18 develop a human immunodeficiency virus (HIV) status-neutral, mobile health clinic model  
19 serving African Americans in Alameda county, a population with the highest rates of HIV  
20 infections in the San Francisco Bay Area; and

21 WHEREAS, This model allows the community to access healthcare in a “one-stop  
22 shop” in a range of services that can improve health disparities; and

23 WHEREAS, In this project, we will engage key stakeholders to refine the delivery  
24 model, and evaluate implementation science outcomes in a six month pilot study; and

25 WHEREAS, The grant does not require an Annual Salary Ordinance Amendment; and

1           WHEREAS, A grant increase of \$95,155 from \$138,357 was approved for the period of  
2     September 1, 2017, through August 31, 2022; and

3           WHEREAS, A request for retroactive approval is being sought because DPH received  
4     the award agreements on October 31, 2019, February 11, 2020, for a project start date of  
5     September 1, 2017, January 5, 2022, for a project start date of September 1, 2021, and on  
6     August 31, 2022, for a project start date of September 1, 2021; and

7           WHEREAS, The grant budget includes a provision for indirect costs in the amount of  
8     \$32,498; now, therefore, be it

9           RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant  
10    in the amount of \$ 233,512 from the NIH through UCSF; and, be it

11          FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and  
12    expend the grant funds pursuant to Administrative Code, Section 10.170-1; and, be it

13          FURTHER RESOLVED, That the Director of Health is authorized to enter into the  
14    Agreement on behalf of the City; and, be it

15          FURTHER RESOLVED, That within thirty (30) days of the Grant Agreement being fully  
16    executed by all parties, the Director of Health shall provide a copy to the Clerk of the Board of  
17    Supervisors for inclusion in the official file.

18  
19  
20  
21  
22  
23  
24  
25

1 Recommended:

Approved:  /s/ \_\_\_\_\_

2

Mayor

3  /s/ \_\_\_\_\_

4 Dr. Grant Colfax

Approved:  /s/ \_\_\_\_\_

5 Director of Health

Controller

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

**File Number:** 220953  
(Provided by Clerk of Board of Supervisors)

**Grant Resolution Information Form**  
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **University of California, San Francisco (UCSF) - Gladstone Center for Acquired Immunodeficiency Syndrome (AIDS) Research**
2. Department: **Department of Public Health  
Population Health Division**
3. Contact Person: **Albert Liu** Telephone: **415-437-7408**
4. Grant Approval Status (check one):  
 Approved by funding agency  Not yet approved
5. Amount of Grant Funding Approved or Applied for: **\$216,197**
- 6a. Matching Funds Required: **\$0**  
b. Source(s) of matching funds (if applicable): **N.A.**
- 7a. Grant Source Agency: **National Institutes of Health (NIH)**  
b. Grant Pass-Through Agency (if applicable): **The Regents of the University of California, San Francisco**
8. Proposed Grant Project Summary:  
**The Healthy Outcomes for People Everywhere (HOPE) Project will develop a human immunodeficiency virus (HIV) status-neutral, mobile health clinic model serving African Americans in Alameda County, a population with the highest rates of HIV infections in the Bay Area. This model allows the community to access healthcare in a “one-stop shop” in a range of services that can improve health disparities. In this project, we will engage key stakeholders to refine the delivery model, and evaluate implementation science outcomes in a 6-month pilot study. This is a cross-county collaboration between the San Francisco Department of Public Health, Acquired Immunodeficiency Syndrome (AIDS) Project of the East Bay (APEB) and California Prostitutes Education Project (CAL-PEP) in Alameda County, East Bay Getting to Zero, and University of California, San Francisco (UCSF).**
9. Grant Project Schedule, as allowed in approval documents, or as proposed:  
Start-Date: **September 1, 2017** End-Date: **August 31, 2022**
- 10a. Amount budgeted for contractual services: **\$0**  
b. Will contractual services be put out to bid? **N.A.**  
c. If so, will contract services help to further the goals of the Department’s Local Business Enterprise (LBE) requirements? **N.A.**  
d. Is this likely to be a one-time or ongoing request for contracting out? **N.A.**

11a. Does the budget include indirect costs?  Yes  No

b1. If yes, how much? **\$29,035**

b2. How was the amount calculated? **Please see table below**

c1. If no, why are indirect costs not included? **N.A.**

Not allowed by granting agency

To maximize use of grant funds on direct services

Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs? **N.A.**

12. Any other significant grant requirements or comments:

**The grant does not require an ASO amendment and partially reimburses the department for the existing positions:**

No.	Class	Job Title	FTE	Start Date	End Date
1	2232	Senior Physician Specialist	0.050	09/01/2019	08/31/2020
2	2233	Supervising Physician Specialist	0.025	09/01/2019	08/31/2020
3	2232	Senior Physician Specialist	0.070	09/01/2021	08/31/2022
4	2232	Senior Physician Specialist	0.050	09/01/2021	08/31/2022
5	2232	Senior Physician Specialist	0.036	09/01/2021	08/31/2022

We respectfully request for approval to accept and expend these funds retroactive to September 1, 2017. The Department received the award on November 4, 2019, February 19, 2020, and January 5, 2022. The CFDA # for this grant is 93.855.

This grant is a multi-year grant and the table below shows the awards/subawards for the same grant. The grant increase was \$8,650 and \$14,631 for FY19-20, and \$54,559 for FY21-22 for a total of \$77,840 and \$138,357 was set up through the Annual Appropriation Ordinance.

Award	Budget Period	AAO	Grant Increase	Amount	Indirect Rate	Project Code
10612sc	9/1/17-8/31/18	27,133			12%	10029377
10612sc01	9/1/18-8/31/19	27,227			12%	10032589
10612sc02	9/1/19-8/31/20	27,999			12%	10034014
10612sc03	9/1/20-8/31/21	27,999			12%	10035527
10612sc04	9/1/21-8/31/22	27,999			12%	10036907
11638sc	9/1/19-8/31/20		14,631		12%	10034014
11730sc	9/1/19-8/31/20		8,650		25%	10034014
13083sc	9/1/21-8/31/22		54,559		25%	10036907
Total		138,357	77,840	216,197		

Project Description: **HD HIV D134 2122 UCSF-CFAR**

Project ID: **10036907**

Proposal ID: **CTR00002063**

Fund ID: **11580**

Version ID: **V101**

Authority ID: **10001**

Activity ID: **0001**

**\*\*Disability Access Checklist\*\*\*(Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- |  |   |  |
|--|---|--|
| <input checked="" type="checkbox"/> Existing Site(s) | <input type="checkbox"/> Existing Structure(s)      | <input type="checkbox"/> Existing Program(s) or Service(s) |
| <input type="checkbox"/> Rehabilitated Site(s)       | <input type="checkbox"/> Rehabilitated Structure(s) | <input type="checkbox"/> New Program(s) or Service(s)      |
| <input type="checkbox"/> New Site(s)                 | <input type="checkbox"/> New Structure(s)           |  |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Toni Rucker, PhD  
(Name)

DPH ADA Coordinator  
(Title)

Date Reviewed: 7/25/2022 | 3:43 PM PDT


DocuSigned by:  
  
7084292F7331F44D...  
 (Signature Required)

**Department Head or Designee Approval of Grant Information Form:**

Dr. Grant Colfax  
(Name)

Director of Health  
(Title)

Date Reviewed: 7/26/2022 | 3:17 PM PDT

DocuSigned by:  
  
20327324732858F  
 (Signature Required)  
 Greg wagner, COO for

**SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH**  
**Population Health**  
**Univerisity of California, San Francisco (UCSF) - Gladstone Center for AIDS Research**  
**September 1, 2017 - August 31, 2022**

		Year 1 Project: 10029377 9/1/17 - 8/31/18	Year 2 Project: 10032589 9/1/18 - 8/31/19	Year 3 Project: 10034014 9/1/19 - 8/31/20	Year 4 Project: 10035527 9/1/20 - 8/31/21	Year 5 Project: 10036907 9/1/21 - 8/31/22	Total Amount
	<b>Personnel -</b>						-
	Senior Physician Specialist	18,700	18,700	9,480	19,230	13,951	80,061
	Senior Physician Specialist			19,230		9,965	29,195
	Senior Physician Specialist					19,230	19,230
	Supervising Physician Specialist			4,740		7,260	12,000
							-
	<b>Fringe benefits</b>	5,526	5,610	11,532	5,769	18,240	46,677
							-
							-
							-
							-
							-
	<b>Indirect Costs</b>	2,907	2,917	6,298	3,000	13,912	29,035
<b>Total</b>		<b>27,133</b>	<b>27,227</b>	<b>51,280</b>	<b>27,999</b>	<b>82,558</b>	<b>216,197</b>



## FDP Cost Reimbursement Subaward

<b>Federal Awarding Agency:</b> National Institutes of Health (NIH)	
<b>Pass-Through Entity (PTE):</b> The Regents of the University of California, San Francisco	<b>Subrecipient:</b> City & County of San Francisco
PTE PI: Monica Gandhi, MD	Sub PI: Albert Liu, MD, MPH
PTE Federal Award No: 5P30A1027763-30	Subaward No: 13083sc
Project Title: UCSF-Gladstone Center for AIDS Research	
<b>Subaward Budget Period:</b>	
Start: 09/01/2021      End: 08/31/2022	Amount Funded This Action (USD): \$ 54,559.00
<b>Estimated Period of Performance:</b>	
Start: 09/01/2021      End: 08/31/2022	Incrementally Estimated Total (USD): \$ 54,559.00

### Terms and Conditions

1. PTE hereby awards a cost reimbursable subaward, (as determined by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for this Subaward are as shown in Attachment 5. In its performance of Subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE.
2. Subrecipient shall submit invoices not more often than monthly and not less frequently than quarterly for allowable costs incurred. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305. All invoices shall be submitted using Subrecipient's standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415(a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party's Financial Contact, shown in Attachment 3A.
3. A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's Financial Contact, as shown in Attachment 3A, not later than 60 days after the final Budget Period end date. The final statement of costs shall constitute Subrecipient's final financial report.
4. All payments shall be considered provisional and are subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient.
5. Matters concerning the technical performance of this Subaward shall be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4.
6. Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this Subaward, and any changes requiring prior approval, shall be directed to the PTE's Authorized Official Contact and the Subrecipient's Authorized Official Contact shown in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party's Authorized Official as shown in Attachments 3A and 3B.
7. The PTE may issue non-substantive changes to the Budget Period(s) and Budget Unilaterally. Unilateral modification shall be considered valid 14 days after receipt unless otherwise indicated by Subrecipient when sent to Subrecipient's Authorized Official Contact, as shown in Attachment 3B.
8. Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
9. Either party may terminate this Subaward with 30 days written notice. Notwithstanding, if the Awarding Agency terminates the Federal Award, PTE will terminate in accordance with Awarding Agency requirements. PTE notice shall be directed to the Authorized Official Contact, and Subrecipient notice shall be directed to the Authorized Official Contact as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable
10. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Work in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions ("RTCs") of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this subaward to comply with all applicable laws, regulations, and requirements.

By an Authorized Official of the PTE:  <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 45%;">Name: _____</div> <div style="width: 10%; text-align: center;">Date</div> <div style="width: 45%; text-align: right;">_____</div> </div> <div style="margin-top: 5px;">Title: _____</div>	By an Authorized Official of the Subrecipient:  <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 45%;">Name: _____</div> <div style="width: 10%; text-align: center;">Date</div> <div style="width: 45%; text-align: right;">_____</div> </div> <div style="margin-top: 5px;">Title: _____</div>
--	---

**Attachment 1**  
**Certifications and Assurances**

Subaward Number:

13083sc

**Certification Regarding Lobbying (2 CFR 200.450)**

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief, that no Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement in accordance with 2 CFR 200.450.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the PTE.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

---

**Debarment, Suspension, and Other Responsibility Matters (2 CFR 200.214 and 2 CFR 180)**

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief that neither the Subrecipient nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any federal department or agency, in accordance with 2 CFR 200.213 and 2 CFR 180.

---

**Audit and Access to Records**

Subrecipient certifies that it will provide PTE with notice of any adverse findings which impact this Subaward. Subrecipient certifies compliance with applicable provisions of 2 CFR 200.501-200.521. If Subrecipient is not required to have a Single Audit as defined by 200.501, Awarding Agency requirements, or the Single Audit Act, then Subrecipient will provide notice of the completion of any required audits and will provide access to such audits upon request. Subrecipient will provide access to records as required by parts 2 CFR 200.337 and 200.338 as applicable.

---

**Program for Enhancement of Contractor Employee Protections (41 U.S.C 4712)**

Subrecipient is hereby notified that they are required to: inform their employees working on any federal award that they are subject to the whistleblower rights and remedies of the program; inform their employees in writing of employee whistleblower protections under 41 U.S.C §4712 in the predominant native language of the workforce; and include such requirements in any agreement made with a subcontractor or subgrantee.

---

The Subrecipient shall require that the language of the certifications above in this Attachment 1 be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

---

**Use of Name**

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

---

**Prohibition on Certain Telecommunication and Video Surveillance Services or Equipment**

Pursuant to 2 CFR 200.216, Subrecipient will not obligate or expend funds received under this Subaward to: (1) procure or obtain; (2) extend or renew a contract to procure or obtain; or (3) enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses covered telecommunications equipment or services (as described in Public Law 115-232, section 889) as a substantial or essential component of any system, or as a critical technology as part of any system.

**Attachment 2**  
**Federal Award Terms and Conditions**

Subaward Number  
**13083sc**

**Required Data Elements**

The data elements required by Uniform Guidance are incorporated **in the attached Federal Award.**

**This Subaward Is:**

Research & Development     Subject to FFATA

Awarding Agency Institute (If Applicable)

Federal Award Issue Date    FAIN    Assistance Listing No.

Assistance Listing Program Title (ALPT)

Key Personnel Per NOA

**General Terms and Conditions**

By signing this Subaward, Subrecipient agrees to the following:

1. To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency's website:

**http://grants.nih.gov/policy/notices.htm**

2. 2 CFR 200 and 45 CFR Part 75.

3. The Federal Awarding Agency's grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at:

**http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf**

4. Research Terms and Conditions, including any Federal Awarding Agency's Specific Requirements found at:

**https://www.nsf.gov/awards/managing/rtc.jsp** except for the following :

- a. No-cost extensions require the written approval of the PTE. Any requests for a no-cost extension shall be directed to the **Administrative** Contact shown in Attachment 3A, not less than 30 days prior to the desired effective date of the requested change.
- b. Any payment mechanisms and financial reporting requirements described in the applicable Federal Awarding Agency Terms and Conditions and Agency-Specific Requirements are replaced with Terms and Conditions (1) through (4) of this Subaward; and
- c. Any prior approvals are to be sought from the PTE and not the Federal Awarding Agency.
- d. Title to equipment as defined in 2 CFR 200.1 that is purchased or fabricated with research funds or Subrecipient cost sharing funds, as direct costs of the project or program, shall vest in the Subrecipient subject to the conditions specified in 2 CFR 200.313.
- e. Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel (defined as listed on the NOA).

5. Treatment of program income: **Additive**

**Special Terms and Conditions:**

**Data Sharing and Access:**

Subrecipient agrees to comply with the Federal Awarding Agency's data sharing and/or access requirements as reflected in the NOA or the Federal Awarding Agency's standard terms and conditions as referenced in General Terms and Conditions 1-4 above.

**No additional requirements**

**Data Rights:**

Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

**Copyrights:**

**Subrecipient Shall Grant** to PTE an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Subrecipient grants to PTE the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its Federal Award.

**Promoting Objectivity in Research (COI):**

Subrecipient must designate herein which entity's Financial Conflicts of Interest policy (COI) will apply: **Subrecipient**

If applying its own COI policy, by execution of this Subaward, **Subrecipient certifies that its policy complies with the requirements of the relevant Federal Awarding Agency as identified herein: NIH - 42 CFR Part 50 Subpart F**

Subrecipient shall report any financial conflict of interest to PTE's Administrative Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.

---

**Work Involving Human or Vertebrate Animals** (Select Applicable Options) No Human or Vertebrate Animals

IRB

 Human Subjects Vertebrate Animals

The PTE requires verification of IRB and/or IACUC approval be sent to the  as required above:

Subrecipient agrees that any non-exempt human and/or vertebrate animal research protocol conducted under this Subaward shall be reviewed and approved by the appropriate Institutional Review Board (IRB) and/or its Institutional Animal Care and Use Committee (IACUC), as applicable and that it will maintain current and duly approved research protocols for all periods of the Subaward involving human and/or vertebrate animal research. Subrecipient certifies that the appropriate IRB and/or IACUC are in full compliance with applicable state and federal laws and regulations. The Subrecipient certifies that any submitted IRB / IACUC approval represents a valid, approved protocol that is entirely consistent with the Project associated with this Subaward. In no event shall Subrecipient invoice or be reimbursed for any human or vertebrate animals related expenses incurred in a period where any applicable IRB / IACUC approval is not properly in place.

---

**Human Subjects Data** (Select One) 

This section left intentionally blank

---

**NIH Terms and Conditions**

The Clinical Trial Indicator in Section IV of the PTE's NOA is stated as:

**Multiple PIs (MPI)****Certificate of Confidentiality:**

The Parties agree that this research funded in whole or in part by the National Institutes of Health ("NIH"), is subject to NIH Policy NOT-OD-17-109 (the "Policy") and therefore is deemed under the Policy to be issued a Certificate of Confidentiality ("Certificate") should the conditions outlined within the Policy apply. Accordingly, the subrecipients who collect or receive identifiable, sensitive information are is required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the "PHS Act").

---

**Additional Terms**

**Attachment 3A**  
**Pass-Through Entity (PTE) Contacts**

Subaward Number:  
13083sc

**PTE Information**

Entity Name: The Regents of the University of California, San Francisco

Legal Address: c/o Office of Sponsored Research, Box 0962  
490 Illinois Street, 4th Floor  
San Francisco, CA 94143-0962 (Use 94158 for Courier and Federal Express)

Website: <http://osr.ucsf.edu/>

**PTE Contacts**

Central Email: CGSubOutTeam@ucsf.edu

Principal Investigator Name: Monica Gandhi, MD

Email: Monica.Gandhi@ucsf.edu Telephone Number:

Administrative Contact Name: Julie Tang

Email: Julie.tang@ucsf.edu Telephone Number:

COI Contact email (if different to above): coiac@ucsf.edu

Financial Contact Name: Rado Lee

Email: Rado.Lee@ucsf.edu Telephone Number:

Email invoices?  Yes  No Invoice email (if different): subcontract@ucsf.edu

Authorized Official Name: Subaward Manager, Research Management Services

Email: CGSubOutTeam@ucsf.edu Telephone Number:

**PI Address:**

same as legal address above

**Administrative Address:**

same as legal address above

**Invoice Address:**

Supply Chain Management - Accounts Payable  
Attn: Subcontracts Desk  
Box 0812  
1855 Folsom Street, Suite 304  
San Francisco, CA 94143-0812

**Attachment 3B**  
**Subrecipient Contacts**

Subaward Number:  
13083sc

**Subrecipient Information for [FFATA](#) reporting**

Entity's DUNS Name:

EIN No.:  Institution Type:

DUNS:  Currently registered in SAM.gov:  Yes  No

Exempt from reporting executive compensation:  Yes  No *(if no, complete 3Bpg2)*

Parent DUNS:  *This section for U.S. Entities:* Zip Code [Look-up](#)

Place of Performance Address Congressional District:  Zip Code+4:

**Subrecipient Contacts**

Central Email:

Website:

Principal Investigator Name:

Email:  Telephone Number:

Administrative Contact Name:

Email:  Telephone Number:

Financial Contact Name:

Email:  Telephone Number:

Invoice/Payment Email:

Authorized Official Name:

Email:  Telephone Number:

**Legal Address:**

**Administrative Address:**

**Payment Address:**

**Attachment 3B-2**  
**Highest Compensated Officers**

Subaward Number:

13083sc

**Subrecipient:**

Institution Name:

PI Name:

**Highest Compensated Officers**

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:

**Attachment 4**  
**Reporting and Prior Approval Terms**

Subaward Number:  
13083sc

Subrecipient agrees to submit the following reports (PTE contacts are identified in Attachment 3A):

**Technical Reports:**

- Monthly technical/progress reports will be submitted to the PTE's Administrative Contact within 15 days of the end of the month.
- Quarterly technical/progress reports will be submitted within 30 days after the end of each project quarter to the PTE's Administrative Contact.
- Annual technical / progress reports will be submitted within 75 days prior to the end of each budget period to the PTE's Principal Investigator. Such report shall also include a detailed budget for the next Budget Period, updated other support for key personnel, certification of appropriate education in the conduct of human subject research of any new key personnel, and annual IRB or IACUC approval, if applicable.
- A Final technical/progress report will be submitted to the PTE's Principal Investigator within 60 days of the end of the Project Period or after termination of this award, whichever comes first.
- Technical/progress reports on the project as may be required by PTE's Principal Investigator in order for the PTE to satisfy its reporting obligations to the Federal Awarding Agency.

**Prior Approvals:**

Carryover:  
Carryover is automatic

**Other Reports:**

- In accordance with 37 CFR 401.14, Subrecipient agrees to notify both the Federal Awarding Agency via iEdison and PTE's Principal Investigator within 60 days after Subrecipient's inventor discloses invention(s) in writing to Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report using Federal Awarding Agency specific forms to the PTE's Principal Investigator within 60 days of the end of the Project Period to be included as part of the PTE's final invention report to the Federal Awarding Agency.  
A negative report is required: No
- Property Inventory Report (only when required by Federal Awarding Agency), specific requirements below.

**Additional Technical and Reporting Requirements:**



**Attachment 5**  
**Statement of Work, Cost Sharing, Indirects & Budget**

Subaward Number:

13083sc

**Statement of Work**

Below  Attached,  pages

If award is FFATA eligible and SOW exceeds 4000 characters, include a *Subrecipient Federal Award Project Description*

**Budget Information**

<b>Indirect Information</b> Indirect Cost Rate (IDC) Applied <input type="text" value="25"/> % Rate Type: <input type="text" value="Other (add in blank box)"/> <input type="text" value="Salary and Benefits"/>	<b>Cost Sharing</b> <input type="text" value="No"/> If Yes, include Amount: \$ <input type="text"/>
---	--

**Budget Details**  Below  Attached,  pages

**Budget Totals**

Direct Costs \$   
Indirect Costs \$   
Total Costs \$

*All amounts are in United States Dollars*

## **City and County of San Francisco**

### **Scope of work**

**Start/End Dates:**

September 1, 2021 – August 31, 2022

**Sub Project Director Name:**

Albert Liu

The scope of work included in the participation of the City and County of San Francisco in the 2021 EHE CFAR/ARC Supplement entitled “HOPE: Developing a Status Neutral, Mobile Health Clinic Model in Alameda County” includes providing overall leadership and scientific direction to the project, including project planning, implementation of stakeholder engagement and implementation pilot, and analysis and dissemination of findings.

**DETAILED BUDGET FOR INITIAL BUDGET PERIOD  
DIRECT COSTS ONLY**

FROM THROUGH  
09/01/21 08/30/22

List PERSONNEL (Applicant organization only)

Use Cal, Acad, or Summer to Enter Months Devoted to Project

Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	FTE	Acad. Mnth	Summer Mnth	INST. BASE SALARY	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
Liu, Albert	PD/PI	0.070	12.00		199,300	13,951	5,580	19,531
Buchbinder, Susan	Co-I	0.050	12.00		199,300	9,965	3,986	13,951
Scott, Hyman	Co-I	0.036	12.00		199,300	7,260	2,904	10,165
<b>SUBTOTALS</b>						<b>31,176</b>	<b>12,471</b>	<b>43,647</b>
CONSULTANT COSTS								0
EQUIPMENT (Itemize)								0
SUPPLIES (Itemize by category)								0
TRAVEL								0
INPATIENT CARE COSTS								0
OUTPATIENT CARE COSTS								0
ALTERATIONS AND RENOVATIONS (Itemize by category)								0
OTHER EXPENSES (Itemize by category)								0
CONSORTIUM/CONTRACTUAL COSTS								0
<b>SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 7a, Face Page)</b>						DIRECT COSTS		<b>43,647</b>
CONSORTIUM/CONTRACTUAL COSTS						25.00%	FACILITIES AND ADMINISTRATIVE COSTS	10,912
<b>TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD</b>								<b>54,559</b>

## BUDGET JUSTIFICATION

Subcontract: City and County of San Francisco

Budget Period: 09/01/2021 through 8/31/2022

**Total Senior Key Personnel Year 1: \$43,647**  
**Includes Fringe Benefits at 40%.**

**Fringe:** Budgeted at 40% of personnel costs (wages), payroll taxes and fringe benefits include employer's share of federal, state, and locally mandated payroll taxes; health, and dental insurance premiums; unemployment and disability insurance premiums; and employer's and employee's contribution to employee retirement plans.

Fringe Benefit Component	Rate
Unemployment Insurance	0.26%
Social Sec-Medicare(HI Only)	1.39%
Social Security (OASDI & HI)	5.94%
Life Insurance	0.02%
Dental Coverage	0.52%
Retiree Health-Match-Prop B	1.00%
Health Service-City Match	8.00%
Retire City Misc	22.87%
<b>TOTAL</b>	<b>40.00%</b>

### **A. PERSONNEL**

**Albert Liu, MD, MPH (CCSF Subcontract Principal Investigator/Supplement Project Director): salary requested at 0.84 calendar months in year 1.** Dr. Liu is Clinical Research Director at Bridge HIV at the San Francisco Department of Public Health and Associate Clinical Professor of Medicine at the University of California, San Francisco (UCSF). Dr. Liu is a well-established, successful, clinical investigator who has been conducting clinical studies developed by NIH HIV/AIDS Clinical Trials Networks for 15 years. As PI, Dr. Liu will be responsible for leading the overall scientific, operational, and administrative aspects of the study.

**Susan Buchbinder, MD (Co-Investigator): salary requested at 0.60 calendar months year 1.**

Dr. Buchbinder is Director of Bridge HIV at the San Francisco Department of Public Health and Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco. She provides scientific leadership in the NIH-sponsored HIV Vaccine Trials Network and HIV Prevention Trials Network and leads several multi-site HIV prevention efficacy trials, with a focus on advancing integrated prevention strategies in diverse populations of MSM and transgender people in the US and globally. Dr. Buchbinder will assist with development of interview guides and survey instruments and analysis and dissemination of findings.

**Hyman Scott, MD, MPH (Co-Investigator): salary requested at 0.43716 calendar months in year 1.**

Dr. Scott is the Medical Director of Clinical Research at Bridge HIV at the San Francisco Department of Public Health (SFDPH), Medical Director of San Francisco AIDS Foundation (SFAF) and Assistant Clinical Professor of Medicine, Division of HIV, ID, Global Medicine, University of California, San Francisco. He currently directs clinical operations at Bridge HIV and leads PrEP implementation within the SFDPH. Dr. Scott will work with Dr. Wilson to prepare the Bridge HIV mobile van for delivery of HIV status neutral services.

C. Equipment Description  
None

D. Travel  
None

E. Participant Support Costs  
None

F. Other Direct Costs  
None

G. Direct Costs: \$43,647

H. Indirect Costs  
Indirect Cost Type: Salaries and Benefits  
Indirect Cost Rate: 25%  
Total Indirect Costs:  
\$10,912

Indirect cost rate based on memo from March 3, 2021 for the Population Health and Prevention-Public Health Division of the City and County of San Francisco. Indirect costs are requested at 25%.

I. Total Direct and Indirect Costs: \$54,559

## **Attachment 6**

### **Notice of Award (NOA) and any additional documents**

- The following pages include the NOA and if applicable any additional documentation referenced throughout this Subaward.
- Not incorporating the NOA or any additional documentation to this Subaward.



Recipient Information	Federal Award Information																										
<p><b>1. Recipient Name</b>            REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE            1855 FOLSOM ST STE 425             SAN FRANCISCO, CA 94143</p> <p><b>2. Congressional District of Recipient</b>            12</p> <p><b>3. Payment System Identifier (ID)</b>            1946036493A6</p> <p><b>4. Employer Identification Number (EIN)</b>            946036493</p> <p><b>5. Data Universal Numbering System (DUNS)</b>            094878337</p> <p><b>6. Recipient's Unique Entity Identifier</b></p> <p><b>7. Project Director or Principal Investigator</b>            Monica Gandhi, MD            Professor Of Clinical Medicine            monica.gandhi@ucsf.edu            (415) 260-6709</p> <p><b>8. Authorized Official</b>            Julie C. Tang            cgawardteam@ucsf.edu            (628) 206-2268</p>	<p><b>11. Award Number</b>            5P30AI027763-30</p> <p><b>12. Unique Federal Award Identification Number (FAIN)</b>            P30AI027763</p> <p><b>13. Statutory Authority</b>            42 USC 241 42 CFR 52</p> <p><b>14. Federal Award Project Title</b>            UCSF-Gladstone Center for AIDS Research</p> <p><b>15. Assistance Listing Number</b>            93.855</p> <p><b>16. Assistance Listing Program Title</b>            Allergy and Infectious Diseases Research</p> <p><b>17. Award Action Type</b>            Non-Competing Continuation</p> <p><b>18. Is the Award R&amp;D?</b>            Yes</p>																										
<p><b>Federal Agency Information</b></p> <p><b>9. Awarding Agency Contact Information</b>            PAULA Acevedo            Grants Management Specialist            NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES            paula.acevedo@nih.gov            301-435-2860</p> <p><b>10. Program Official Contact Information</b>            Eric William Refsland             NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES            eric.refsland@nih.gov            301-761-7193</p>	<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr style="background-color: #e1eef6;"> <th colspan="2" style="text-align: center; padding: 5px;">Summary Federal Award Financial Information</th> </tr> </thead> <tbody> <tr style="background-color: #e1eef6;"> <td colspan="2" style="padding: 5px;"><b>19. Budget Period Start Date 09/01/2021 – End Date 08/31/2022</b></td> </tr> <tr> <td style="padding: 5px;"><b>20. Total Amount of Federal Funds Obligated by this Action</b></td> <td style="text-align: right; padding: 5px;">\$3,354,700</td> </tr> <tr> <td style="padding: 5px;">    20 a. Direct Cost Amount</td> <td style="text-align: right; padding: 5px;">\$2,688,868</td> </tr> <tr> <td style="padding: 5px;">    20 b. Indirect Cost Amount</td> <td style="text-align: right; padding: 5px;">\$665,832</td> </tr> <tr> <td style="padding: 5px;"><b>21. Authorized Carryover</b></td> <td style="text-align: right; padding: 5px;">\$0</td> </tr> <tr> <td style="padding: 5px;"><b>22. Offset</b></td> <td style="text-align: right; padding: 5px;">\$0</td> </tr> <tr> <td style="padding: 5px;"><b>23. Total Amount of Federal Funds Obligated this budget period</b></td> <td style="text-align: right; padding: 5px;">\$3,354,700</td> </tr> <tr> <td style="padding: 5px;"><b>24. Total Approved Cost Sharing or Matching, where applicable</b></td> <td style="text-align: right; padding: 5px;">\$0</td> </tr> <tr> <td style="padding: 5px;"><b>25. Total Federal and Non-Federal Approved this Budget Period</b></td> <td style="text-align: right; padding: 5px;">\$3,354,700</td> </tr> <tr> <td colspan="2" style="text-align: center; border-top: 1px dashed black; padding: 5px;">-----</td> </tr> <tr style="background-color: #e1eef6;"> <td colspan="2" style="padding: 5px;"><b>26. Project Period Start Date 03/01/1997 – End Date 08/31/2022</b></td> </tr> <tr> <td style="padding: 5px;"><b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b></td> <td style="text-align: right; padding: 5px;">\$20,628,036</td> </tr> </tbody> </table> <p><b>28. Authorized Treatment of Program Income</b>            Additional Costs</p> <p><b>29. Grants Management Officer - Signature</b>            Ann W. Devine</p>	Summary Federal Award Financial Information		<b>19. Budget Period Start Date 09/01/2021 – End Date 08/31/2022</b>		<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$3,354,700	20 a. Direct Cost Amount	\$2,688,868	20 b. Indirect Cost Amount	\$665,832	<b>21. Authorized Carryover</b>	\$0	<b>22. Offset</b>	\$0	<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$3,354,700	<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0	<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$3,354,700	-----		<b>26. Project Period Start Date 03/01/1997 – End Date 08/31/2022</b>		<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$20,628,036
Summary Federal Award Financial Information																											
<b>19. Budget Period Start Date 09/01/2021 – End Date 08/31/2022</b>																											
<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$3,354,700																										
20 a. Direct Cost Amount	\$2,688,868																										
20 b. Indirect Cost Amount	\$665,832																										
<b>21. Authorized Carryover</b>	\$0																										
<b>22. Offset</b>	\$0																										
<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$3,354,700																										
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0																										
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$3,354,700																										
-----																											
<b>26. Project Period Start Date 03/01/1997 – End Date 08/31/2022</b>																											
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$20,628,036																										
<b>30. Remarks</b>																											
Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.																											



---

**SECTION I – AWARD DATA – 5P30AI027763-30**

**Principal Investigator(s):**

Monica Gandhi, MD

**Award e-mailed to:** cgrasteam@ucsf.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$3,354,700 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to The Regents of the UCSF in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number P30AI027763. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Ann W. Devine  
Grants Management Officer  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

---

**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**



Salaries and Wages	\$899,738
Fringe Benefits	\$371,513
Personnel Costs (Subtotal)	\$1,271,251
Consultant Services	\$15,000
Materials & Supplies	\$57,433
Travel	\$10,000
Other	\$1,010,016
Subawards/Consortium/Contractual Costs	\$325,168

Federal Direct Costs	\$2,688,868
Federal F&A Costs	\$665,832
Approved Budget	\$3,354,700
Total Amount of Federal Funds Authorized (Federal Share)	\$3,354,700
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$3,354,700</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$3,354,700**

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
30	\$3,354,700	\$3,354,700

**Fiscal Information:**

Payment System Identifier: 1946036493A6  
Document Number: PAI027763G  
PMS Account Type: P (Subaccount)  
Fiscal Year: 2021

IC	CAN	2021
HD	8014713	\$133,730
AI	8017495	\$241,366
MD	8019794	\$60,662
AI	8040373	\$64,449
AI	8051385	\$310,505
AG	8470707	\$59,994
DK	8472284	\$64,449
AI	8472375	\$1,551,551
DA	8472633	\$220,732
CA	8474821	\$353,496
HL	8475178	\$293,766

**NIH Administrative Data:**

PCC: A26A / OC: 41025 / Released: Devine, Ann 09/02/2021  
Award Processed: 09/03/2021 12:26:01 AM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5P30AI027763-30**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – STANDARD TERMS AND CONDITIONS – 5P30AI027763-30**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) P30AI027763. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e.,

awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at: [https://grants.nih.gov/grants/rppr/rppr\\_instruction\\_guide.pdf](https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf). Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. *Note that data reported within Section I of the Interim and Final RPPR forms will be made public and should be written for a lay person audience.*

NIH strongly encourages electronic submission of the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final invention statement may be e-mailed as PDF attachments to: [NIHCloseoutCenter@mail.nih.gov](mailto:NIHCloseoutCenter@mail.nih.gov).

Hard copy: Paper submissions of the final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or mailed to:

National Institutes of Health  
Office of Extramural Research  
Division of Central Grants Processing  
Grants Closeout Center  
6705 Rockledge Drive  
Suite 5016, MSC 7986  
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)  
Bethesda, MD 20817 (for other courier/express deliveries only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

This award is funded by the following list of institutes. Any papers published under the auspices of this award must cite the funding support of all institutes.

Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD) National Institute Of Allergy And Infectious Diseases (NIAID) National Institute On Minority Health And Health Disparities (NIMHD) National Institute On Aging (NIA) National Institute Of Diabetes And Digestive And Kidney Diseases (NIDDK) National Institute On Drug Abuse (NIDA) National Cancer Institute (NCI) National Heart, Lung, And Blood Institute (NHLBI)
--

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Additional Costs

---

**SECTION IV – AI SPECIFIC AWARD CONDITIONS – 5P30AI027763-30**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

The conditions of award incorporate the following items proposed by the applicant in the grant application dated **07/28/2016**, and include the modifications, based on the recommendations of the Initial Review Committee, submitted by the applicant on **03/07/2017**.

- CFAR Policies and Procedures
- CFAR Management Plan - CFAR Strategic Plan
- CFAR Advisory Committee(s) authority and responsibility

Any changes in these items from the Notice of Award will require concurrence of NIH.

Under governing regulations, grant funds shall not be expended for Research projects or activity involving human subjects or animal subjects without the approval of the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) in accordance with the approved Assurance on file with the Office of Human Research Protection (OHRP) or the Office of Laboratory Animal Welfare (OLAW), respectively.

THIS REGULATION ALSO APPLIES TO ALL DEVELOPMENTAL PROJECTS FUNDED THROUGH THE CFAR'S DEVELOPMENTAL CORE. IT IS THE CFAR INSTITUTION'S RESPONSIBILITY TO ENSURE THAT ALL DEVELOPMENTAL AWARDS INVOLVING HUMAN SUBJECTS OR ANIMAL SUBJECTS HAVE IRB OR IACUC APPROVAL IN ACCORDANCE WITH THE APPROVED ASSURANCE ON FILE WITH OHRP OR OLAW.

No funds may be provided for projects involving foreign sites unless approval is received by email notification. This includes developmental awards that have foreign involvement. If developmental awards involve international studies, prior approval must be received by NIAID Program and Grants Management Staff.

~~~~~

This award provides supplemental funds of \$ 310,505 Total Costs for **Developing a Status Neutral, Mobile Health Clinic Model in Alameda County**. These funds provide support for the period **09/01/2021 - 08/31/2022**. These funds are restricted for stated purpose, in request dated **04/19/2021**, from **University of California, San Francisco**, and may not be rebudgeted or used for any other purpose, without NIAID awarding unit approval.

~~~~~

This Notice of Award (NoA) includes funds for activity with **Vitalant Research Institute** in the amount of **\$18,934 (\$11,961 direct costs + \$6,973 F&A costs)**.

This Notice of Award (NoA) includes funds for activity with **San Francisco Department of Public Health** in the amount of **\$27,999** (**\$24,999** direct costs + **\$3,000** F&A costs).

This Notice of Award (NoA) includes funds for activity with **J. David Gladstone Institutes** in the amount of **\$116,584** (**\$61,750** direct costs + **\$54,834** F&A costs).

~~~~~

The Research Performance Progress Report (RPPR), Section G.9 (Foreign component), includes reporting requirements for all research performed outside of the United States. Research conducted at all foreign sites must be reported in your RPPR:

**Bafoussam Regional Hospital Blood Bank, CAMEROON**  
**Safe Blood for Africa Foundation, CAMEROON**  
**University of Yaounde, CAMEROON**  
**University Teaching Hospital of Yaounde, CAMEROON**  
**Yaounde Central Hospital Blood Bank, CAMEROON**  
**Dr. Luis Morillo King Hospital, DOMINICAN REPUBLIC**  
**Hospital Luis L. Bogaert, DOMINICAN REPUBLIC**  
**La Universidad Autonoma de Santo Domingo (UASD), DOMINICAN REPUBLIC**  
**Institut National de la Transfusion Sanguine, FRANCE**  
**Kerman university of Medical Sciences, IRAN**  
**Tehran university of Medical Sciences, IRAN**  
**Family Aids Care and Education Services (FACES) - Kisumu, KENYA**  
**Kenya Medical Research Institute (KEMRI), KENYA**  
**Sindo Sub-County Hospital, KENYA**  
**Lebanese American University, LEBANON**  
**MENA Organization for Services, Advocacy, Integration & Capacity Building (MOSAIC), LEBANON**  
**LoveYourself, Inc., PHILLIPPINES**  
**Bunumbu Community Health Center, SIERRA LEONE**  
**Daru Community Health Center, SIERRA LEONE**  
**Jaima Nimikoro Community Health Center, SIERRA LEONE**  
**Jojoima Community Health Center, SIERRA LEONE**  
**Kainkordu Community Health Center, SIERRA LEONE**  
**Kamara Community Health Center, SIERRA LEONE**  
**Kangama Community Health Center, SIERRA LEONE**  
**Koindu Community Health Center, SIERRA LEONE**  
**Nixon Hospital, SIERRA LEONE**  
**Partners in Health, SIERRA LEONE**  
**Pendembu Community Health Center, SIERRA LEONE**  
**Tombodu Community Health Center, SIERRA LEONE**  
**Yengema Community Health Center, SIERRA LEONE**  
**Yormandu Community Health Center, SIERRA LEONE**  
**Human Sciences Research Council, SOUTH AFRICA**  
**University of KwaZulu-Natal, SOUTH AFRICA**  
**AIDS Health Care Foundation - Uganda Cares, UGANDA**  
**AIDS Support Organization (TASO), UGANDA**  
**Bale Health Center, UGANDA**  
**Bishop Asili Health Center, UGANDA**  
**Good Health for Women Project (GHWP), UGANDA**  
**Infectious Diseases Institute, UGANDA**  
**Infectious Disease Research Collaboration, UGANDA**  
**Kalisizo Hospital, UGANDA**  
**Kojja Health Center, UGANDA**  
**Makerere University College of Health Sciences, UGANDA**  
**Masaka Regional Referral Hospital, UGANDA**  
**Medical Research Council at Uganda Virus Research Institute, UGANDA**  
**MRC/UVRI and LSHtm Uganda Research Unit, UGANDA**  
**Mulago Hospital, UGANDA**  
**Mwea Health Center, UGANDA**  
**Nakasongola Health Center, UGANDA**  
**St. Balikuddembe Market Clinic, UGANDA**

**Uganda Malaria Surveillance Project - Infectious Disease RC, UGANDA**  
**Uganda National Council for Science and Technology (UNCST), UGANDA**  
**Centre for Infectious Disease Research in Zambia, ZAMBIA**  
**Chongwe Clinic (Zambia Ministry of Health), ZAMBIA**  
**George Clinic and Chingwe Clinic, ZAMBIA**  
**Kanyama Clinic, ZAMBIA**  
**University Teaching Hospital and Kanyama Clinic, ZAMBIA**

~~~~~

This award may include collaborations with and/or between foreign organizations. Please be advised that short term travel visa expenses are an allowable expense on this grant, if justified as critical and necessary for the conduct of the project.

~~~~~

This award is co-funded by **NIA, NIDCR, NINR, NHLBI, NICHD, NIDA, NIDDK, NIMHD, NIMH, NCI**, and the **National Institute of Allergy and Infectious Diseases**. All publications, posters, oral presentations at scientific meetings, seminars, and any other forum in which results of this co-funded research are presented must include a formal acknowledgement of the **NIA, NIDCR, NINR, NHLBI, NICHD, NIDA, NIDDK, NIMHD, NIMH, NCI and NIAID** support, citing the NIAID grant number as identified on this award document.

~~~~~

This award is subject to the Clinical Terms of Award referenced in the NIH Guide for Grants and Contracts, July 8, 2002, NOT AI-02-032. These terms and conditions are hereby incorporated by reference, and can be accessed via the following World Wide Web address: <https://www.niaid.nih.gov/grants-contracts/niaid-clinical-terms-award> All submissions required by the NIAID Clinical Terms of Award must be forwarded electronically or by mail to the responsible NIAID Program Official identified on this Notice of Award.

**SPREADSHEET SUMMARY**

**AWARD NUMBER:** 5P30AI027763-30

**INSTITUTION:** The Regents of the UCSF

Budget	Year 30
Salaries and Wages	\$899,738
Fringe Benefits	\$371,513
Personnel Costs (Subtotal)	\$1,271,251
Consultant Services	\$15,000
Materials & Supplies	\$57,433
Travel	\$10,000
Other	\$1,010,016
Subawards/Consortium/Contractual Costs	\$325,168
TOTAL FEDERAL DC	\$2,688,868
TOTAL FEDERAL F&A	\$665,832
TOTAL COST	\$3,354,700

Facilities and Administrative Costs	Year 30
F&A Cost Rate 1	26%
F&A Cost Base 1	\$2,219,277
F&A Costs 1	\$577,012
F&A Cost Rate 2	61.5%
F&A Cost Base 2	\$144,423
F&A Costs 2	\$88,820

**City and County of San Francisco**

**Department of Public Health**



**London N. Breed  
Mayor**

**TO: Angela Calvillo, Clerk of the Board of Supervisors**

**FROM: Dr. Grant Colfax  
Director of Health**

**DATE: 7/22/2022**

**SUBJECT: Grant Accept and Expend**

**GRANT TITLE: University of California, San Francisco (UCSF) - Gladstone  
Center for Acquired Immunodeficiency Syndrome (AIDS)  
Research - \$216,197**

---

Attached please find the original and 1 copy of each of the following:

- Proposed grant resolution, original signed by Department
- Grant information form, including disability checklist
- Budget and Budget Justification
- Grant application: Not Applicable. No application submitted.
- Agreement / Award Letter
- Other (Explain):

**Special Timeline Requirements:**

**Departmental representative to receive a copy of the adopted resolution:**

Name: Gregory Wong (greg.wong@sfdph.org) Phone: 554-2521

Interoffice Mail Address: Dept. of Public Health, 101 Grove St # 108

Certified copy required Yes

No